Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions.

Melanie RijsbergenRianne RijneveldMarina ToddGary L FeissStijn T P KouwenhovenKoen D QuintDirk C J G van AlewijkMaurits N C de KoningErica S KlaassenJacobus BurggraafRobert RissmannMariëtte I E van Poelgeest

Published in: British journal of clinical pharmacology (2020)

Topical omiganan appears to be safe in patients with AGW and vulvar HSIL and reduced human papillomavirus load after 12 weeks of treatment in AGW patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
early stage
diabetic rats
radiation therapy
patient reported outcomes
drug induced
sentinel lymph node
neoadjuvant chemotherapy
combination therapy
endothelial cells
wound healing
patient reported